Drug Profile
Avelumab - Merck KGaA
Alternative Names: Anti-CD274-monoclonal-antibody; Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck KGaA; BAVENCIO; MSB-0010718C; PF-06834635Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator EMD Serono; Merck Biopharma; Merck KGaA
- Developer 4SC; AIO Studien gGmbH; Array BioPharma; Baylor College of Medicine; Chong Kun Dang; Dana-Farber Cancer Institute; Debiopharm; eFFECTOR Therapeutics; EMD Serono; Forty Seven; Fred Hutchinson Cancer Research Center; G1 Therapeutics; Gachon University Gil Medical Center; Hellenic Cooperative Oncology Group; Hoosier Cancer Research Network; Hospices Civils de Lyon; Istituto Oncologico Veneto; Johannes Gutenberg-University Mainz; M. D. Anderson Cancer Center; Merck Biopharma; Merck KGaA; National Cancer Institute (USA); Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Syndax Pharmaceuticals; Transgene; University College London; University of Birmingham; University of California, San Diego; University of Iowa; University of North Carolina at Chapel Hill; University of Padua; Vaccinex; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem Oncology; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Yes - Gastric cancer; Merkel cell carcinoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Merkel cell carcinoma; Renal cell carcinoma; Urogenital cancer
- Phase III Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
- Phase II Bladder cancer; Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Gestational trophoblastic disease; Glioblastoma; Haemangiosarcoma; HER2 negative breast cancer; HER2 positive breast cancer; Hodgkin's disease; Intestinal cancer; Leiomyosarcoma; Liver cancer; Lymphoma; Malignant thymoma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Osteosarcoma; Penile cancer; Peripheral T-cell lymphoma; Peritoneal cancer; Prostate cancer; Rectal cancer; Recurrent respiratory papillomatosis; Small cell lung cancer; Squamous cell cancer; Testicular cancer; Thymoma
- Phase I/II Anal cancer; Bone metastases; Cervical cancer; Liposarcoma; Oropharyngeal cancer; Pancreatic cancer; Vulvovaginal cancer
- Phase I CNS cancer; Follicular lymphoma
- No development reported Acute myeloid leukaemia; Meningioma
Most Recent Events
- 01 Mar 2024 G1 Therapeutics terminates a phase II PRESERVE3 trial in Bladder cancer (Metastatic disease, First-line therapy, Combination therapy, Late-stage disease) in Georgia, Hungary, Spain, France, USA (IV) as the sponsor is no longer pursuing trial for the indication (NCT04887831)
- 05 Dec 2023 Efficacy and adverse events data from the phase II trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 20 Oct 2023 Updated efficacy and adverse event data from a phase II AveNEC trial in Neuroendocrine tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)